2 completed, 1 terminated. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow PDS Biotechnology Corp.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy - Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer | Phase 3 | Terminated | PDS Biotechnology Corp. | 12 | 2025-05-30 | 2026-09-02 |
| Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC Pembrolizumab (KEYTRUDA®) and PDS0101 - Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer | Phase 2 | Completed | PDS Biotechnology Corp. | 95 | 2021-03-29 | 2025-10-01 |
| An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101 R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7 - High-risk HPV Infection and Biopsy-proven CIN1 | Phase 1 | Completed | PDS Biotechnology Corp. | 12 | 2014-02-01 | 2018-12-13 |
Head and Neck Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Neoplasms, Squamous Cell (1)
pembrolizumab (2)
United States (3) · Ireland (1) · Puerto Rico (1) · United Kingdom (1)
David T Schaaf, MD (1) · Kirk V Shepard, MD (1)